 |
 |
| Lumibird's 2024 sales revenues were boosted by "buoyant" sales of products used to treat dry eye disease, following the receipt of two key CE Mark approvals. In November the France-headquartered company said it had begun exploring a potential sale of its medical division. Photo: Lumibird. |
| © 2025 SPIE Europe |
|
